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Schizophrenia is strongly familial yet rarely (if ever) exhibits classical Mendelian inheritance patterns. The advent 
of large-scale genotyping and sequencing projects has yielded large data sets with higher statistical power in an 
effort to uncover new associations with schizophrenia. Here, we review the challenges in dissecting the genetics 
of schizophrenia and provide an update of the current understanding of the underlying genomics. We discuss the 
breadth of susceptibility alleles, including those that may occur with low frequency and high disease risk, such as 
the 22q11.2 hemideletion, as well as alleles that may occur with greater frequency but convey a lower risk of schizo-
phrenia, such as variants in genes encoding subunits of the voltage-gated L-type calcium channel. Finally, we pro-
vide an overview of the clinical implications for the diagnosis and treatment of schizophrenia based on progress in 
understanding the underlying genetic basis.
Introduction
Schizophrenia is a debilitating psychiatric disorder that remains 
enigmatic long after its first description over 100 years ago. In 
spite of considerable research efforts, its pathophysiology remains 
poorly understood. As with most psychiatric conditions, the clini-
cal and research definitions of schizophrenia are based on constel-
lations of signs and symptoms (1) and are thus usually considered 
“disorders” instead of “diseases.” Unlike many other medical con-
ditions, there are no objective clinical or pathological features of 
high sensitivity and specificity to enable greater precision in the 
diagnosis of schizophrenia. The onset of schizophrenia is typically 
in adolescence or early adulthood, and the course of illness is often 
lifelong and typified by exacerbations, remissions, substantial 
residual symptoms, and functional impairment. Schizophrenia 
thus has an immense impact on public health and is among the 
five leading causes of disability worldwide (2). Individuals affected 
by schizophrenia have elevated morbidity and mortality, a lifetime 
risk of suicide exceeding 10%, and substantial comorbidity with 
other psychiatric disorders, including major depressive disorder 
and substance abuse (refs. 3–5 and Table 1). The significant soci-
etal, familial, and personal impacts of schizophrenia underscore 
the pressing need for more effective preventive, diagnostic, and 
treatment strategies.
Major efforts by the psychiatric genetics community — aided 
by exceptional advances in technology and knowledge of the 
genome — have transformed this field and have identified multi-
ple robust and replicable findings. We believe it timely to provide 
an update on the genomics of schizophrenia, along with consid-
eration of its implications.
Risk factors for schizophrenia
Results from over 40 years of epidemiological and genetic epidemi-
ological studies have converged on the conclusion that schizophre-
nia is a complex disorder, with both genetic and environmental 
determinants. Family history is a strong and widely replicated 
risk factor, and the heritability of schizophrenia (the proportion 
of variance in liability due to additive genetic factors) is relatively 
high, exceeding 60% in two national family studies and 80% in twin 
studies (Table 1). Multiple lines of inquiry also show important 
environmental influences that affect risk for schizophrenia (refs. 
6–9 and Table 1). Perinatal and early childhood events, including 
maternal stress and infection, growing up in urbanized areas, and 
being part of an immigrant group all increase risk of developing 
schizophrenia (9). Viral infections of the central nervous system 
during development may also play an important role (10).
The logic behind genomic approaches to schizophrenia
Assessment of the genome is increasingly complete, tractable, and 
cost effective. It is now routine to screen the whole genome for 
many types of genetic changes in large samples. In contrast, envi-
ronmental assessment is often considerably more difficult — there 
is no single comprehensive technology to screen an individual’s 
“environome,” prospective assessments in large samples can be 
prohibitively expensive, and retrospective assessments are prone 
to measurement error. Thus, even as both genes and environment 
are involved in the etiology of schizophrenia, many researchers 
have reasoned that capitalizing on the family history risk factor 
via genomic studies is a logical starting point.
Due to its high heritability and strong familial associations, 
genetic approaches are critically important for the study of schizo-
phrenia. Yet, until recently, progress had been disappointingly 
slow. The Human Genome Project, the International HapMap 
Project, the 1000 Genomes Project, and ENCODE have yielded 
unprecedented increases in knowledge about the sequence of the 
human genome, the location and prevalence of genetic variation, 
and biological regulatory processes (11–14). These advances have 
provided a fertile ground for research discoveries about the genetic 
basis of schizophrenia and other complex disorders.
In the last five years, as the psychiatric genetics community has 
adopted rigorous standards for the analysis of genetic data, repli-
cation and confidence in genetic findings has increased (15, 16). 
These advances have resulted from a convergence of factors. The 
large-scale genome projects mentioned above (e.g., HapMap) also 
catalyzed technological advances in genotyping, sequencing, analy-
Conflict of interest: Patrick F. Sullivan was on the scientific advisory board of 
Expression Analysis.
Citation for this article: J Clin Invest. 2013;123(11):4557–4563. doi:10.1172/JCI66031.
review
4558 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 11   November 2013
sis, and bioinformatics as well as marked decreases in cost. In addi-
tion, accrual of very large sample sizes, which has only been pos-
sible through consortia, has been critical for achieving improved 
statistical power. One of many consortia in psychiatry, the Psychiat-
ric Genomics Consortium (PGC) (17), has orchestrated large-scale 
mega-analyses for schizophrenia and other major psychiatric dis-
orders (18–20). The PGC has more than 375 investigators from 22 
countries and has approximately 125,000 cases and controls with 
genome-wide association study (GWAS) data under analysis and is 
the largest consortium in the history of psychiatry.
Genomic results for schizophrenia
Multiple approaches have been applied to understand the genetic 
basis of schizophrenia. Accumulating data indicate a role for both 
rare and common variants in increasing risk for schizophrenia. 
Current studies suggest multiple robust and replicable genomic 
findings for schizophrenia (Figure 1). These susceptibility alle-
les occur with varying degrees of frequency and confer different 
risks of disease development, as discussed below. Surprisingly, 
the genetic basis for schizophrenia has multiple points of conver-
gence with other psychiatric disorders that have different clinical 
features, such as autism and bipolar disorder (20–26). With fur-
ther work, it is possible, and perhaps likely, that these results will 
lead to revisions in psychiatric nosology or the fundamental ways 
in which we classify and approach these disorders.
Mendelian forms of schizophrenia. Notably, no Mendelian forms 
of schizophrenia (i.e., rare mutations with deterministic effects) 
have been identified via standard medical genetics approaches 
or genomics studies (Figure 1A, i). Although generations of 
physicians have evaluated the family histories of probands with 
schizophrenia, few (if any) highly com-
pelling instances of pedigrees in which 
schizophrenia segregates in Mendelian 
fashion exist. While some consider dis-
rupted in schizophrenia 1 (DISC1) as an 
example of this class of mutation, criti-
cal review of the empirical data does not 
strongly support this conclusion (27). 
The notion that schizophrenia exhibits 
non-Mendelian inheritance was bol-
stered by a sequencing study focusing 
on individuals with exceptionally ear-
ly-onset and treatment-resistant schizo-
phrenia, which identified no clear exonic 
mutations (28). Mendelian subforms 
have been identified for multiple other 
psychiatric disorders (e.g., Alzheimer’s 
disease, autism, and mental retardation).
Copy number variants. Changes in the 
number of copies of DNA from the 
expected values are known as copy num-
ber variants (CNVs) and result from the 
deletion (del) or duplication (dup) of 
a relatively large genomic region (29). 
As a consequence, the “dosages” of one 
or more genes in the region are altered 
and can exert a profound effect on risk 
for disease. Multiple rare CNVs are now 
established risk factors for psychiat-
ric disorders, including schizophrenia, 
mental retardation, and autism (22, 29–33). This class of vari-
ants has a high genotypic relative risk (Figure 1A, ii).
Eight CNVs have a strong effect on disease risk (genotypic relative 
risks 4-20) and have been consistently associated with psychiatric 
disorders (29, 30, 34). Two CNVs impact single genes: 2p16.3 del 
(neurexin 1 [NRXN1]) (35) and 7q36.3 dup (vasoactive intestinal 
peptide receptor 2 [VIPR2]) (36). Others alter the dosages of many 
genes: 1q21.1 del/dup (34 genes) (37–41), 3q29 del (19 genes) (34, 
37, 42), 7q11.23 dup (25 genes) (37, 43, 44), 15q11.2 dup (70 genes) 
(39, 45), 15q13.3 del/dup (12 genes) (38, 39, 46), 16p13.11 dup (47, 
48) (8 genes), 16p11.2 del/dup (29 genes) (49–53), 17q12 del (18 
genes) (54), and 22q11.2 del/dup (53 genes) (45, 55).
The studies that established these associations evaluated cases 
and controls. Without parental data, these CNVs could have been 
inherited from a parent or arisen de novo. De novo CNVs have 
been widely studied in autism (44). In schizophrenia, there are 
fewer studies, although increased rates of de novo CNVs have been 
reported in cases with schizophrenia (37).
Although these CNVs are rare and relatively potent risk factors, they 
often involve many genes and are not specific, as risk is often increased 
for multiple psychiatric disorders. These complexities limit their util-
ity for understanding the specific genes contributing to schizophre-
nia. Further work is needed to probe the contribution of the genes 
within many of these multigenic CNVs in order to understand their 
contribution to disease. Nonetheless, pathway analysis of genes in 
these CNVs suggests an overrepresentation of genes associated with 
neuronal function, providing a context for future research (37, 56).
The 16p11.2 CNV has been associated with both autism and 
schizophrenia. Deletion and duplication of this CNV are also asso-




Lifetime prevalence 0.4% (98)
Morbidity Leading worldwide cause of disability (2)
 Licit and illicit drug and alcohol use disorders (4)
 Cardiovascular disease (99)
 Type 2 diabetes mellitus (100)
Mortality 12- to 15-year decrease in life expectancy (99, 101)
Lifetime cost $1.4 million per person (102)
Epidemiological risk factors (9) Family history





Heritability 64% (95% CI, 62%–67%), Swedish national family study (6)
 67% (95% CI, 64%–71%), Danish national family study (8)
 81% (95% CI, 73%–90%), twin study meta-analysis (7)
Genetic loci (30) No Mendelian variants
 CNVs
 Common SNPs
 Uncommon/rare exonic variants
Estimated SNPs 6,000–10,000 independent common variants that together
  account for ~50% of variance in liability (66)
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(49, 50, 52). The 16p11.2 CNV encompasses 29 genes; systematic 
overexpression and inhibition of each gene in zebrafish suggested 
that the potassium channel tetramerization domain containing 
13 gene (kctd13) might be the key determinant in the region, as the 
brain size phenotypes mirrored those in humans (57).
Uncommon or rare exonic variation. Recent improvements in tech-
nology have enabled the evaluation of most of the protein-coding 
regions of the genome (the “exome”) via high-throughput sequenc-
ing. This is currently an area of intense interest, because the confi-
dent identification of rare or uncommon exonic variants of strong 
effect could be particularly valuable (Figure 1A, iii). Any such vari-
ant would pinpoint a single key gene and probably be amenable to 
current molecular biology and neurobiology methods.
A few small exome sequencing studies of schizophrenia have been 
published (larger studies have been submitted for publication). 
Xu et al. carried out exome sequencing of 231 trios with no fam-
ily history (i.e., “sporadic” cases) and 34 unaffected trios (58, 59). 
Four genes with modest statistical evidence were highlighted by the 
authors (dihydropyrimidine dehydrogenase [DPYD], laminin, α 2 
[LAMA2], transformation/transcription domain-associated pro-
tein [TRRAP], and vacuolar protein sorting 39 [VPS39]), and the 
authors suggested that in aggregate cases with schizophrenia had 
an increased burden of de novo variation (58). An exome sequencing 
study of 14 schizophrenia probands and their parents found more 
de novo mutations (60). Evaluation of 166 schizophrenia cases in a 
search for variants associated with treatment resistance or notably 
strong family history failed to identify any exonic variants (28). Gul-
suner et al. conducted exome sequencing in family constellations 
selected to maximize the chances of observing de novo mutations; 
no genes were identified, although there was a slight excess of de 
novo mutations predicted to damage proteins (61).
The task has proved more challenging than some investigators 
believed it would be a few years ago (62). A hypothetical model of 
the etiology of schizophrenia is that each case has a determinis-
tic (possibly de novo) exon mutation. These mutations are very 
likely unique to individuals, although such mutations might show 
some bias for a selected but large set of genes. This model has been 
formally rejected for autism (63) and is rather inconsistent with 
Figure 1
The genetic landscape of schizophrenia. (A) 
The allelic spectrum of schizophrenia. Shown 
are high-confidence empirical findings of the 
contribution of rare and common variants 
to the genotypic relative risk for developing 
schizophrenia. The x axis depicts the log10 
of allele frequency in controls, and the y axis 
depicts the point estimate for log10 of the geno-
typic relative risk. (i) No Mendelian variants for 
schizophrenia are known. A Mendelian form of 
schizophrenia would be expected to be rare 
with a very high genotypic relative risk (>50). 
(ii) CNVs associated with schizophrenia (rep-
resented by diamonds) are uncommon or rare 
and have an intermediate to high genotypic rel-
ative risks. (iii) Whole-exome sequencing stud-
ies have yet to identify protein-altering variants 
in this region, but the extant studies are few 
and small. (iv) High-confidence exclusion zone 
defined by risk allele prevalence >0.1 and 
genotypic relative risk >1.16, in which no loci 
have been identified despite statistical power 
nearing 100%. (v) Approximately 22 common 
variants have been significantly associated 
with schizophrenia to date (red circles). Com-
mon variants have a low genotypic relative risk 
individually but together account for more than 
50% of the heritability of schizophrenia. (B) 
Expanded view of v, identifying the genomic 
regions achieving genome-wide significance. 
Circles denote the 22 common variants that 
have been significantly associated with schizo-
phrenia; green circles represent long intergenic 
noncoding RNAs (lincRNAs).
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the accumulated data for schizophrenia. However, searches for 
this class of variation should be part of a balanced approach to 
understand the genetic basis of schizophrenia, as any such variant 
is likely amenable to molecular methods.
GWASs. The identification of candidate loci for complex dis-
eases and traits has been accelerated by GWASs (15). As with 
other complex disorders (16, 64), common variation seems to be 
at the heart of the genetic risk of schizophrenia, and at least some 
of these associations replicate in samples from people of East 
Asian and European descent (30, 65). Large collaborations like 
the PGC have dramatically increased sample sizes and provided 
statistical power to identify relatively subtle effects of loci that 
meet an appropriately rigorous significance level (P < 5 × 10–8). 
Indeed, there is a high-confidence exclusion zone (e.g., risk allele 
prevalence >0.1 and genotypic relative risk >1.16) in which no 
loci have been identified despite statistical power approaching 
100% (Figure 1A, iv).
While understanding the determinants of schizophrenia may 
seem daunting, the emergence of themes among these regions is 
encouraging. For example, a recent GWAS (66) has identified 22 
regions with genome-wide significance (Figure 1A, v), 13 novel 
regions and many that replicated previous findings (major his-
tocompatibility complex [MHC], WW domain binding protein 
1-like [C10orf26, also known as WBP1L], DPYD-MIR137, serologi-
cally defined colon cancer antigen 8 [SDCCAG8], MMP16, calcium 
channel, voltage-dependent, L-type, α 1C subunit [CACNA1C], and 
a large region containing multiple genes and members of the inter-
α-trypsin inhibitor heavy chain gene family [ITIH3-ITIH4 region]) 
(18, 19, 24, 26, 67–69).
Several themes have emerged from the replicated GWAS findings, 
which provide a framework for future work. Calcium signaling has 
emerged as a potentially important theme in the etiology of schizo-
phrenia. Calcium signaling has been previously implicated in bipolar 
disorder, autism, and schizophrenia (18, 19, 24, 70). A recent GWAS 
replicated the association of CACNA1C (Cav1.2, P = 5.2 × 10–12 at the 
intronic SNP rs1006737) with schizophrenia, and the β2 subunit 
(Cav β2, encoded by CACNB2) also reached genome-wide significance 
(P = 1.3 × 10–10 at the intronic SNP rs17691888) (20, 66). The voltage-
gated L-type calcium channel is formed from the multimerization of 
the pore-forming α1c subunit (encoded by CACNA1C), which directly 
interacts with the intracellular β2 subunit (encoded by CACNB2), and 
a third extracellular membrane anchored α2δ subunit (71, 72). Cal-
cium channels have been extensively studied in neuroscience and 
are critically important for learning, memory, and synaptic plas-
ticity (73–75). Several Mendelian disorders result from deleterious 
mutations in calcium channel subunits. Mutations in CACNA1C 
and CACNB2 underlie Brugada syndrome types 3 and 4 (76). CAC-
NA1C mutations cause Timothy syndrome, a multiorgan disorder, 
including cognitive impairment and autism spectrum disorder (70). 
Disruption of calcium channels can result in widespread effects, due 
to their known engagement in large protein networks at the synapse, 
as well as in multiple calcium-dependent signaling cascades.
The microRNA 137 (encoded by MIR137) has also emerged as a 
potentially important risk factor for schizophrenia, given its strong 
GWAS association with schizophrenia (P = 1.7 × 10–12) (66). Given 
the known ability of microRNAs to regulate degradation or trans-
lational inhibition of large numbers of genes, it is notable that mul-
tiple proven and predicted miR-137 targets are also significantly 
associated with schizophrenia, including CACNA1C, transcription 
factor 4 (TCF4), CUB and Sushi multiple domains 1 (CSMD1), and 
C10orf26 (18, 77). miR-137 has been implicated in neurodevel-
opment, adult neural stem cell proliferation and differentiation, 
and dendritic arborization (78–80). These findings support future 
research ventures investigating the role of signaling pathways con-
taining miR-137 targets in the pathogenesis of schizophrenia.
The current results strongly indicate that schizophrenia is 
highly polygenic, with disease burden being distributed across 
numerous loci (67). In the largest schizophrenia GWAS yet 
reported (21,246 schizophrenia cases and 38,072 controls), 22 
loci reached genome-wide significance (66). Yet larger studies 
are in progress — the PGC has reported a preliminary GWAS 
mega-analysis of 25,000 schizophrenia cases and 28,000 controls 
and increased the number of genome-wide significance associ-
ations to 62 (81). The PGC is now preparing a report based on 
36,000 schizophrenia cases and will increase the number of cases 
with GWAS data to 60,000. Bayesian power calculations based 
on empirical effect sizes project the identification of over 500 
genome-wide significant and independent loci (66). Therefore, 
we expect considerable progress in this area in the next 1–2 years.
The genetic architecture of schizophrenia
The nature of the genetic architecture of schizophrenia — the 
number of loci and the defining characteristics of each locus — 
has been debated for decades. We now have empirical data that 
directly addresses the underlying nature of schizophrenia. The 
polygenicity of schizophrenia is incontrovertible. Based on avail-
able data, the genetic architecture of schizophrenia is diverse and 
includes loci across the allelic spectrum (Figure 1): many common 
variants of subtle effect, rare but highly penetrant CNVs, and pos-
sibly exome variants.
Understanding the polygenicity of schizophrenia is a major 
task in the years to come. One parsimonious hypothesis is that 
one or more biological pathway(s) unifies many of the empir-
ical findings for schizophrenia. However, the mechanisms by 
which these common variants increase risk for schizophrenia 
are still unknown. The biological roles of these variants and 
how they interact with other genes and the environment are 
not now understood.
The loci identified to date are probably a fraction of the vari-
ants that exist. Multiple studies have shown that cases have a 
greater burden of schizophrenia risk alleles compared with con-
trols (P < 10–25) (30). We recently estimated that large numbers 
of independent and mostly common SNPs (95% credible inter-
vals, 6,300–10,200 SNPs) underlie risk for schizophrenia (66). 
This estimate is supported by a recent study that estimated the 
number of SNPs with an effect on schizophrenia and bipolar 
disorder to be over 12,000 (82). Each SNP confers a very small 
increase in risk, but collectively they account for around 50% of 
the total variance in liability to schizophrenia (66). If the heri-
tability of schizophrenia is around 65% (6, 8), this suggests that 
common genetic variation accounts for the lion’s share of the 
heritability of schizophrenia.
Sources of controversy
Genetic approaches to schizophrenia have been applied for over 40 
years. Even casual readers in this area may be aware that dissect-
ing the genetics of schizophrenia has been challenging. There have 
been many claims of identification of causal genetic risk factors 
for schizophrenia, and yet few claims prior to 2008 have stood the 
test of time and replication (83, 84). Such claims have occasionally 
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engendered considerable media attention. As one example, evi-
dence from large and carefully conducted studies do not support 
DISC1 as a risk factor for schizophrenia (27). A prominent excep-
tion that has shown robust and replicable associations with schizo-
phrenia is the 22q11.2 del CNV present in approximately 0.3% to 
2% of schizophrenia cases (34, 85).
We believe these difficulties and the attendant, unwelcome con-
troversies have arisen for two main reasons. First, as discussed 
above, the genetic variants that increase risk for schizophrenia dif-
fer from what had often been assumed of a genetic architecture, 
with a prominent role for numerous loci of subtle effect. Despite 
significant efforts, there are no compelling examples of determin-
istic genetic variants acting in a Mendelian fashion as yet. From a 
statistical perspective, this genetic architecture implies that very 
large sample sizes are required (i.e., tens of thousands of cases) for 
any type of association study as well as for genome-wide linkage 
approaches (86, 87).
Thus, with the immense benefits of hindsight, the poor past 
replicability of genetic associations for schizophrenia can be at 
least partially understood on statistical grounds. If sample sizes 
are orders of magnitude too small, true associations will almost 
always be missed due to low power. Similarly, claims of association 
have an overwhelming probability of arising by chance and thus 
can be expected not to replicate. Since 2008, with the advent of 
far larger sample sizes, multiple genomic findings have replicated 
relatively well across samples.
A second source of controversy has arisen more recently. Multi-
ple authors have argued that elucidation of genetic architectures 
for complex biomedical diseases (including schizophrenia) that 
are characterized by large numbers of common variants of sub-
tle effects is effectively unhelpful (88, 89). The argument rests 
on two main points. The first point is the “missing heritability” 
objection that the identified variants explain only a small frac-
tion of the variance in liability to a disorder. The counterargu-
ment is that if the genetic architecture has thousands of variants 
(as appears to be the case for many complex diseases) (15, 16, 
64), models containing a small fraction of the thousands of truly 
associated variants could only explain small amounts of varia-
tion. Indeed, if modeled more inclusively, common variation can 
explain substantial fractions of the variance in liability, so that, 
effectively, variation is “hidden” by inadequately powered studies 
rather than “missing” (15, 64).
The second point is that elucidation of complex genetic architec-
tures is unhelpful for attaining the goals of personalized (“preci-
sion”) medicine. The crux of this objection is the intention of con-
ducting genomic searches: to generate rational biological starting 
points for idiopathic psychiatric disorders or to improve disease 
prediction and tailor treatments? The answer here depends on 
the researcher. Personalized medicine in regard to schizophrenia 
will be a difficult goal, given its genetic architecture. We note that 
this was predictable: the risk of schizophrenia to the co-twin of 
a monozygotic twin with schizophrenia is only around 50% (7), 
and this single observation strongly limits the potential role of 
genetic variation for personalized medicine. However, for many 
in the field, the primary goal of carrying out genetic studies has 
been biology. Each genetic finding is a potential etiological clue. 
Many of these findings will fall into a discrete number of biolog-
ical, developmental, or functional pathways whose elucidation 
and characterization could dramatically advance knowledge of the 
pathophysiology of schizophrenia. As early examples of this, tran-
scriptional modules with altered gene expression in postmortem 
brain samples of individuals with schizophrenia (90) and autism 
(91) were enriched for smaller P values in GWAS.
Clinical perspectives
The major implication of the schizophrenia findings to date is 
that the number of common variants potentially involved in 
increased risk for schizophrenia is in the thousands. While in sil-
ico approaches can yield initial hypotheses about these variants, 
bench research will be necessary for an understanding of the 
biology of the identified loci. Furthermore, the numerous rel-
evant loci will need to be dissected, not with standard methods 
and individual efforts, but through the targeting of networks, 
like processes involving miR-137 and the calcium channel sig-
naling pathway.
However, the immediate clinical implications are few. While 
currently available calcium channel antagonists have not demon-
strated efficacy in the treatment of schizophrenia, this does not 
discount CACNA1C as a target for future research (92). Finally, one 
must consider that, as many approved antipsychotics increase the 
cardiac QT interval, genetic variation in calcium channel subunits 
could aid in the identification of patients at a higher risk of sud-
den cardiac death (93, 94).
Clinical assessment of several rare CNVs of strong effect could 
now be warranted. The identification schizophrenia cases with 
one of these variants (approximately 0.5%–2% of all cases) could 
potentially be relevant for reproductive decisions of patients upon 
genetic counseling, the etiology of psychiatric disorders in other 
family members, and evaluation of comorbid general medical dis-
eases. For example, many of these CNVs are associated with epi-
lepsy, and their presence should prompt particularly careful con-
sideration of the cryptic presence of a seizure disorder. Although 
these CNVs should be uncommon in any clinical sample, the yield 
is probably higher than that shown by brain magnetic resonance 
imaging in first-episode psychosis that is commonly performed in 
many centers (95, 96).
Emerging research directions
The new technologies, tools, and results from large samples have 
revitalized research into the fundamental basis of schizophrenia. 
As noted above, studies conducting more complete evaluation of 
the role of exonic variation should be published in 2014. More-
over, identifying parsimonious biological hypotheses — perhaps 
in the form of pathways whose dysfunction typifies schizophrenia 
— that might unify the polygenic findings for schizophrenia will 
likely become a major research focus, as any such pathways could 
provide considerable etiological insight and perhaps suggest new 
avenues for treatment interventions. We would like to highlight 
some of the avenues of research that might prove to be particularly 
informative in the near future.
First, we can now use genomic results in a research context to 
attempt to disentangle the notable but poorly understood clinical 
heterogeneity of schizophrenia. For example, it is now straight-
forward to assess individual “burden,” the number of common 
risk alleles, CNVs, and exonic deleterious variation. How do these 
measures of genetic liability to schizophrenia relate to symptom 
patterns, probability of treatment response, and clinical course?
Second, as noted above, schizophrenia results from both 
genetic and environmental sources of causation. We can mea-
sure environmental and genetic risk factors in populations. How 
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do specific environmental and genetic variables act to predis-
pose or protect against schizophrenia? Are the effects additive 
or are there gene-environment interactions?
Third, we can now assess epigenetic variation (97) with consid-
erable resolution. However, these studies remain expensive and 
have several notable experimental difficulties. These studies rep-
resent a “four-dimensional” problem in that they require sampling 
of the correct tissue at the appropriate point in time. Obtaining 
high-quality postmortem brain tissue is also nontrivial. Perhaps 
the most critical issue is delineating cause from consequence. 
Which epigenetic changes reflect the basic disease process and 
which result from a worse lifestyle, antipsychotic treatment, and/
or drugs of abuse?
Conclusions
In the last five years, the psychiatric genetics community has 
achieved remarkable progress in elucidating the genetic basis 
of schizophrenia. A convergence of factors facilitated these 
advances, including large-scale genome projects, technologi-
cal innovations, and the accrual of large sample sets. We now 
have genomic data that directly address the underlying nature 
of schizophrenia: the genetic architecture of schizophrenia is 
diverse and includes many common variants of subtle effect, 
some rare but highly penetrant CNVs, and possibly exome vari-
ants. This renewed understanding of the genetic architecture of 
schizophrenia has reinvigorated the psychiatric genetics com-
munity and promises to provide further insight into schizophre-
nia. Widespread collaboration will be necessary to assess the bio-
logical relevance of these genomic findings in order to facilitate 
maximal progress.
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